Evaluation of the additive effect of interferon α 2b with monthly intravitreal injection of bevacizumab in refractory diabetic macular edema.

Based on our finding, IFN causes an additional CMT reduction in comparison to Bevacizumab monotherapy, and the reduction was more prominent in the IFN sub-tenon injection group (− 117 μm in sub-tenon group at month 3 vs − 49 μm in IFN drop, and − 36 μm in Bevacizumab monotherapy); however, it can be attributed to the relatively small sample size of the study in detecting the difference in data with wide standard deviation that this difference did not reach statistical significance.

also in 111,027 other papers